Table 3. Clinical and histopathological predictors of response (complete or partial), clinical benefit (response or disease stabilisation), progression-free survival (PFS) and overall survival (OAS) with significance levels below 10% (P<0.1) in univariate and multivariate analyses RR=related risk; 95% CI=95% confidence interval.

	Variable	RR	95% CI	P-value
Response
Univariate	—	—	—	—
Multivariate	Her-2/neu phosphorylation	3.08	0.85–11.20	0.088
Benefit
Univariate	Her-2/neu phosphorylation	3.23	0.81–2.97	0.098
Multivariate	—	—	—	—
PFS
Univariate	Grade 3+Her-2/neu overexpression	0.44	0.20–0.95	0.036
	Her-2/neu phosphorylation	0.41	0.21–0.82	0.012
	Higher number of metastatic sites	2.09	1.21–3.63	0.009
	Good performance status	0.61	0.35–1.05	0.074
Multivariate	Grade 3+Her-2/neu overexpression	0.34	0.12–0.93	0.037
	Presence of visceral metastases	0.38	0.17–0.86	0.020
	Her-2/neu phosphorylation	0.38	0.18–0.81	0.012
	Higher number of metastatic sites	2.66	1.33–5.32	0.006
OAS
Univariate	Grade 3+Her-2/neu overexpression	0.11	0.04–0.27	<0.001
	Serum Her-2/neu at baseline	1.00	1.00–1.00	0.076
	Higher number of metastatic sites	4.71	2.10–10.56	<0.001
	Good performance status	0.28	0.13–0.60	0.001
Multivariate	Higher number of metastatic sites	3.79	1.55–9.26	0.003
	Grade 3+Her-2/neu overexpression	0.15	0.05–0.48	0.001